CClinicalTrials.gg
CompletedNCT03982784Updated Nov 13, 2019

TQLB for Postoperative Pain After Laparoscopic Partial Nephrectomy

An interventional study of single-injection TQLB(transmuscular quadratus lumborum block) and Morphine given as IPCA(intravenous patient controlled analgesia) in Laparoscopic Renal Surgery, Pain Management and Nerve Block, sponsored by Cui Xulei. Completed at 1 site in China. Open to participants aged 17 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Cui Xulei · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
17 Years to 80 Years
Sex
All
01

Study summary

This prospective, randomized study,control study aims to compare the analgesic effect,opioids consumption,quality of recovery,length of hospital stay,et al. between single-injection QLB(quadratus lumborum block)+ intravenous patient-controlled analgesia (IPCA) and intravenous patient-controlled analgesia (IPCA) alone in patients undergoing laparoscopic partial nephrectomy.

02

Conditions studied

  • Laparoscopic Renal Surgery
  • Pain Management
  • Nerve Block

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Cui Xulei is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-70 yrs
  • American Society of Anesthesiologists physical statusⅠ-Ⅲ
  • Undergo laparoscopic partial nephrectomy
  • Informed consent

Exclusion criteria

Exclusion Criteria:

  • A known allergy to the drugs being used
  • Coagulopathy, on anticoagulants
  • Analgesics intake, history of substance abuse
  • Participating in the investigation of another experimental agent
  • Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    single-injection TQLB(transmuscular quadratus lumborum block)

    Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)

    Procedure: single-injection TQLB(transmuscular quadratus lumborum block) · Drug: Morphine given as IPCA(intravenous patient controlled analgesia)

  • Active comparator
    Control

    postoperative IPCA is given alone

    Drug: Morphine given as IPCA(intravenous patient controlled analgesia)

Interventions

  • Proceduresingle-injection TQLB(transmuscular quadratus lumborum block)

    Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance

  • DrugMorphine given as IPCA(intravenous patient controlled analgesia)

    PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.

06

What researchers measure

Primary outcomes

  1. cumulative morphine consumption 8 hours after surgery

    Time frame: at the 8 hours after surgery

Secondary outcomes

  1. cumulative morphine consumption at other time points after surgery

    Time frame: at 0, 2, 4, 12, 24 and 48 hours after surgery

  2. The pain scores(at rest or on activity) determined by the numeric rating scale (NRS, 0-10)

    NRS is an internationally recognized pain scale with 11 points ranging from 0 to 10 points, with 0 defined as no pain and 10 defined as the worst pain imaginable.

    Time frame: at 0, 2, 4, 8,12, 24, 48 and 72 hours after surgery

  3. episodes of nausea and vomiting

    Time frame: within 24 hours after the surgery

  4. ambulation time

    time from the end of the surgery to the first time to out-of-bed activity

    Time frame: within the 5 days after surgery

  5. time of recovery of bowl movement

    time from the end of the surgery to the first time of bowl movement

    Time frame: within the 5 days after surgery

  6. patient satisfaction with anesthesia

    Patient satisfaction with anesthesia was assessed using a 5-point scale (5: very satisfied; 4: satisfied; 3: neither satisfied nor dissatisfied; 2: dissatisfied; 1: very dissatisfied)

    Time frame: at 48 hours after surgery

  7. quality of recovery evaluated by the self-assessment 15-item quality of recovery (QoR) scale

    QoR is a 15-item questionnaire which will score on a scale of 0-10 pertaining to patient's comfort, support system, pain, well-being, and ability to carry out daily activities, where 0 indicates none of the time and 10 indicates all of the time

    Time frame: at 72 hours and 120 hours after the sugery

  8. postoperative length of hospital stay

    time to patient's discharge

    Time frame: within 2 weeks after the surgery

07

Study locations

1 site
  • Cui Xulei
    Beijing, Beijing 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03982784
Lead sponsor
Cui Xulei
Responsible party
Cui Xulei (attending physician, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Jun 12, 2019
Start date
Jun 10, 2019
Primary completion
Nov 1, 2019
Completion
Nov 10, 2019
Last update
Nov 13, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion